| Anyone interested in purchasing Glycosmedia should contact the Editor-in-Chief Jim Young to discuss. [email protected]
Semaglutide improved UACR in adults with overweight/obesity and type 2 diabetes. In participants with normal kidney function, semaglutide did not have an effect on eGFR decline (Diabetes Care)
Verapamil partially preserved stimulated C-peptide secretion at 52 weeks compared with placebo and was well tolerated in children and adolescents with newly diagnosed type 1 diabetes (JAMA)
Intensive diabetes management with automated insulin delivery did not affect the decline in pancreatic C-peptide secretion at 52 weeks in youths with newly diagnosed type 1 diabetes (JAMA)
The evidence supporting the use of continuous glucose monitoring technology in type 2 diabetes is growing and it may provide a novel intervention for improving glycaemic control post infarct (Diabetes Research and Clinical Practice)
In this real-world type 2 diabetes population, discontinuation of GLP-1 RA treatment was associated to a higher risk of major cardiovascular events, in both subjects with and without a history of CV events (Cardiovascular Diabetology )
We hope that this document will pragmatically support those involved in the day-to-day care of people with type 2 diabetes in the “here and now”, with the aim of maximising the benefits and minimising harm (ABCD)
Associations were found between genetic liability to type 2 diabetes and an increased risk of a broad range of GDs, highlighting the importance of GD prevention in patients with type 2 diabetes (Diabetes Care)
The PIONEER clinical development programme for oral semaglutide currently comprises nine phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 10,000 adults with type 2 diabetes in total. Oral semaglutide 3 mg, 7 mg and 14 mg are approved under the brand name Rybelsus®, indicated for type 2 diabetes (Novo Nordisk)
| 